Brief: BriaCell Announces TSXV Acceptance Of Normal Course Issuer Bid
22/09/2021 14:18
Sept 22 (Reuters) - Briacell Therapeutics Corp BCT.V :
* BRIACELL ANNOUNCES TSXV ACCEPTANCE OF NORMAL COURSE ISSUER
BID
* BRIACELL THERAPEUTICS - PURSUANT TO BUYBACK, CO MAY
PURCHASE UP
TO 1.3 MILLION COMMON SHARES AND UP TO 411,962 PUBLICLY TRADED
BCTXW WARRANTS IN TOTAL
Source text for Eikon: ID:nGNX125XPh
Further company coverage: BCT.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study